Silvana MORELLO | BIOTECHNOLOGICAL DRUGS AND PERSONALIZED THERAPIES
Silvana MORELLO BIOTECHNOLOGICAL DRUGS AND PERSONALIZED THERAPIES
cod. 0760300041
BIOTECHNOLOGICAL DRUGS AND PERSONALIZED THERAPIES
| 0760300041 | |
| DIPARTIMENTO DI FARMACIA | |
| EQF7 | |
| PHARMACY | |
| 2025/2026 |
| YEAR OF COURSE 5 | |
| YEAR OF DIDACTIC SYSTEM 2023 | |
| AUTUMN SEMESTER |
| SSD | CFU | HOURS | ACTIVITY | |
|---|---|---|---|---|
| BIO/14 | 6 | 48 | LESSONS |
| Objectives | |
|---|---|
| THE COURSE AIMS TO PROVIDE KNOWLEDGE AND UNDERSTANDING OF THE PROPERTIES AND USES OF BIOTECHNOLOGY PRODUCTS IN PHARMACOLOGY AND THE MAIN TOOLS FOR THE STUDY OF THE PHENOTYPIC AND GENOTYPIC CHARACTERISTICS OF EACH INDIVIDUAL FOR THE PERSONALIZATION OF THERAPY. AT THE END OF THE COURSE, THE STUDENT WILL KNOW: • THE BIOCHEMICAL AND PHARMACOLOGICAL CHARACTERISTICS, ADVERSE REACTIONS AND THERAPEUTIC AND CLINICAL APPLICATIONS OF BIOTECHNOLOGICAL DRUGS; • BASIC PRINCIPLES OF INNOVATIVE BIOTECHNOLOGICAL THERAPIES, SUCH AS GENE AND CELL THERAPY; • PHARMACOLOGICAL, GENETIC AND CLINICAL BASIS OF PERSONALIZED THERAPY THE STUDENT APPLYING THE ACQUIRED SKILLS MUST BE ABLE TO: • ADDRESSING AND MANAGING THE PROPER USE OF BIOTECHNOLOGICAL MEDICINES, • IDENTIFY THE BEST THERAPIES BASED ON THE PHENOTYPIC AND GENOTYPIC CHARACTERISTICS OF AN INDIVIDUAL |
| Prerequisites | |
|---|---|
| REQUIRED FOUNDATION COURSES: PHARMACOLOGY AND PHARMACOTHERAPY |
| Contents | |
|---|---|
| THE TEACHING COURSE INCLUDES 48 HOURS OF LESSONS (6 CREDITS) ON THE FOLLOWING TOPICS: -CONCEPTS OF PERSONALIZATION OF THERAPY AND PRECISION MEDICINE/GENETIC VARIANTS-POLYMORPHISMS IN PERSONALIZED THERAPY AND RELEVANCE IN PHARMACOLOGY (2 HOURS) -USE OF GENETIC ENGINEERING IN PHARMACOLOGY (2 HOURS) TYPES AND CHARACTERISTICS OF BIOTECHNOLOGY DRUGS (2 HOURS): -RECOMBINANT AND MODIFIED PROTEINS, CLASSIFICATION OF CLINICALLY USED PROTEINS; -MONOCLONAL ANTIBODIES AND ANTIBODY DERIVATIVES: STRUCTURE, ACTIVITY AND RECYCLING FCRN -PHARMACOKINETICS. ADME, RESCUE MECHANISM AND FACTORS INFLUENCING MABS CLEARANCE (4 HOURS) -PHARMACODYNAMICS OF BIOTECHNOLOGICAL DRUGS (2 HOURS) -ADVERSE EFFECTS OF BIOTECHNOLOGY DRUGS (2 HOURS) -OLIGONUCLEOTIDES AS DRUGS: CLASSIFICATION AND MECHANISM OF ACTION. PHARMACOKINETICS AND TOXICOLOGY (4 HOURS) -BIOTECHNOLOGY DRUGS AND TARGETED THERAPIES IN ONCOLOGY (10 HOURS) -BIOTECHNOLOGY DRUGS FOR INFLAMMATORY, IMMUNE-MEDIATED DISEASES AND INFECTIONS (2 HOURS) -BIOTECHNOLOGICAL DRUGS FOR CARDIOVASCULAR DISEASES (2 HOURS) -BIOTECHNOLOGY DRUGS FOR CENTRAL NERVOUS SYSTEM DISEASES (2 HOURS) -BIOTECHNOLOGY DRUGS FOR ENDOCRINE DISEASES (4 HOURS): -BIOTECHNOLOGY DRUGS FOR RESPIRATORY DISEASES (2 HOURS) -ADVANCED CELL THERAPIES IN REGENERATIVE MEDICINE (2 HOURS) - GENE THERAPY (2 HOURS) -GENDER/SEX PHARMACOLOGY (2 HOURS) |
| Teaching Methods | |
|---|---|
| THE COURSE CONSISTS OF LECTURES THAT TAKE PLACE IN THE CLASSROOM BY USING POWERPOINT PROJECTIONS. PARTICIPATION IN FRONTAL TEACHING IS MANDATORY . THE FREQUENCY WILL BE VERIFIED USING THE EASYBADGE AUTOMATIC DETECTION SYSTEM PROVIDED BY THE UNIVERSITY. |
| Verification of learning | |
|---|---|
| THE ACHIEVEMENT OF THE OBJECTIVES IS CERTIFIED BY PASSING AN EXAMINATION WITH ASSESSMENT IN THIRTIETH. THE EXAM CONSISTS OF AN ORAL TEST, LASTING UP TO 30 MINUTES, WHICH CONSISTS OF AN INTERVIEW WITH QUESTIONS AND DISCUSSION ON THE THEORETICAL CONTENTS INDICATED IN THE TEACHING PROGRAMME AND IS AIMED AT ASCERTAINING THE LEVEL OF KNOWLEDGE AND UNDERSTANDING ACHIEVED BY THE STUDENT, AND TO VERIFY THE EXPOSURE CAPACITY BY USING THE APPROPRIATE TERMINOLOGY AND THE ABILITY TO ORGANISE THE TOPICS INDEPENDENTLY. THE SCORE OF THE ORAL EXAM IS AIMED AT EVALUATING THE THEORETICAL STUDY OF THE STUDENT. THE MINIMUM SCORE WILL BE ATTRIBUTED TO THE STUDENT SHOWING KNOWLEDGE ABOUT THE FUNDAMENTALS OF BIOTECHNOLOGICAL DRUGS AND INNOVATIVE THERAPIES. THE PRAISE CAN BE AWARDED TO STUDENTS WHO WILL REACH THE MAXIMUM MARK OF 30/30 AND WILL PROVE TO BE ABLE TO INDEPENDENTLY APPLY KNOWLEDGE AND SKILLS ACQUIRED IN CONTEXTS OTHER THAN THOSE PROPOSED IN CLASS. |
| Texts | |
|---|---|
| -FARMACI BIOTECNOLOGICI E TERAPIA PERSONALIZZATA. ASPETTI FARMACOLOGICI E CLINICI; CEA, 1 ED 2020 (ZANICHELLI). |
BETA VERSION Data source ESSE3 [Ultima Sincronizzazione: 2025-09-14]
